By Kashish Tandon (Reuters) -Shares of India's Glenmark Pharmaceuticals jumped 10% to a record high on Friday, a day after ...

Ichnos Glenmark Innovation subsidiary IGI Therapeutics has signed an exclusive licensing agreement with AbbVie for ISB 2001, ...

The stock's fall snapped a three-day winning streak.

Glenmark Pharmaceuticals Ltd.’s licensing pact with AbbVie Inc. for its blood cancer drug is boosting optimism over Indian ...

Glenmark Pharma's exclusive licensing deal with AbbVie for ISB-2001 could be transformative, offering significant upside ...

The healthcare industry is a behemoth, with annual expenditures totaling $4.9 trillion in the United States alone. It's a ...

Glenmark Pharmaceuticals' shares surged 10% to an all-time high of ₹2,094 following the announcement of an exclusive ...

AbbVie Inc. defeated class action claims it misled investors about the role kickbacks played in the success of its arthritis ...

With a $2-billion cancer drug deal in its pocket, Glenmark’s licensing agreement with AbbVie not only unlocks a potential ...

It is the second licensing deal that AbbVie has negotiated this year for a trispecific for multiple myeloma, coming in the ...

HSBC and Axis Capital are more bullish on its transformative impact and future growth prospects for Glenmark, while Nuvama ...

Glenmark Pharmaceuticals' share prices surge 10% on exclusive licensing agreement with AbbVie for ISB 2001 trispecific ...